{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:23:04Z","timestamp":1773688984205,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.bbrc.2012.06.017","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T22:51:56Z","timestamp":1339541516000},"page":"697-702","source":"Crossref","is-referenced-by-count":57,"title":["Plasma amyloid-\u03b2 oligomers level is a biomarker for Alzheimer\u2019s disease diagnosis"],"prefix":"10.1016","volume":"423","author":[{"given":"L.","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.W.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.S.C.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.Q.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.W.L.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.M.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.S.L.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2012.06.017_b0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer\u2019s disease","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.bbrc.2012.06.017_b0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Mechanism of disease: Alzheimer\u2019s Disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2012.06.017_b0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2012.06.017_b0020","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1074\/jbc.270.13.7013","article-title":"Amyloid beta protein (A beta) in Alzheimer\u2019s disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43)","volume":"270","author":"Gravina","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2012.06.017_b0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0304-3940(01)01657-3","article-title":"Elevated plasma amyloid beta-peptide 1\u201342 and onset of dementia in adults with Down syndrome","volume":"301","author":"Schupf","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbrc.2012.06.017_b0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1471-4159.2004.02385.x","article-title":"Clearing amyloid through the blood-brain barrier","volume":"89","author":"Zlokovic","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbrc.2012.06.017_b0035","first-page":"605","article-title":"Clearance of Alzheimer\u2019s Abeta peptide: the many roads to perdition","volume":"43","author":"Tanzi","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.bbrc.2012.06.017_b0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bbr.2008.02.016","article-title":"Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior","volume":"192","author":"Selkoe","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbrc.2012.06.017_b0045","doi-asserted-by":"crossref","first-page":"29639","DOI":"10.1074\/jbc.R800016200","article-title":"Structural classification of toxic amyloid oligomers","volume":"283","author":"Glabe","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2012.06.017_b0050","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"A\u03b2 oligomers: a decade of discovery","volume":"101","author":"Walsh","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbrc.2012.06.017_b0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2012.06.017_b0060","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"St George-Hyslop, P., and Westaway, D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2012.06.017_b0065","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2012.06.017_b0070","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2012.06.017_b0075","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/nm790","article-title":"And St George-Hyslop, P, Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4\u201310 and inhibit cytotoxicity and fibrillogenesis","volume":"8","author":"McLaurin","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2012.06.017_b0080","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","article-title":"Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer\u2019s disease","volume":"75","author":"Dodel","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbrc.2012.06.017_b0085","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","article-title":"18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease","volume":"30","author":"Relkin","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbrc.2012.06.017_b0090","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer\u2019s Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2012.06.017_b0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0197-0186(02)00050-5","article-title":"Abeta toxicity in Alzheimer\u2019s disease: globular oligomers (ADDLs) as new vaccine and drug targets","volume":"41","author":"Klein","year":"2002","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bbrc.2012.06.017_b0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0022-510X(96)00143-8","article-title":"Amyloid beta protein in plasma from patients with sporadic Alzheimer\u2019s disease","volume":"141","author":"Tamaoka","year":"1996","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbrc.2012.06.017_b0105","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/archneur.60.7.958","article-title":"Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels","volume":"60","author":"Fukumoto","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbrc.2012.06.017_b0110","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A","article-title":"Plasma amyloid beta-peptide 1\u201342 and incipient Alzheimer\u2019s disease","volume":"46","author":"Mayeux","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbrc.2012.06.017_b0115","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","article-title":"Plasma A[beta]40 and A[beta]42 and Alzheimer\u2019s disease: relation to age, mortality, and risk","volume":"61","author":"Mayeux","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2012.06.017_b0120","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/archneur.57.1.100","article-title":"Plasma and cerebrospinal fluid levels of amyloid beta proteins 1\u201340 and 1\u201342 in Alzheimer disease","volume":"57","author":"Mehta","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbrc.2012.06.017_b0125","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0197-4580(04)81166-7","article-title":"Analysis of plasma A\u03b242 as a premorbid marker for late onset Alzheimer\u2019s disease","volume":"25","author":"Graff-Radford","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbrc.2012.06.017_b0130","first-page":"75","article-title":"Plasma beta amyloid and cytokine profile in women with Alzheimer\u2019s disease","volume":"29","author":"Baranowska-Bik","year":"2008","journal-title":"Neuro. Endocrinol. Lett."},{"key":"10.1016\/j.bbrc.2012.06.017_b0135","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/nm0798-832","article-title":"Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer\u2019s patients by fluorescence correlation spectroscopy","volume":"4","author":"Pitschke","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2012.06.017_b0140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JAD-2008-14201","article-title":"A method for the detection of amyloid-beta1-40, amyloid-beta1-42 and amyloid-beta oligomers in blood using magnetic beads in combination with flow cytometry and its application in the diagnostics of Alzheimer\u2019s disease","volume":"14","author":"Santos","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbrc.2012.06.017_b0145","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archneurol.2008.565","article-title":"A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease","volume":"66","author":"Xia","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbrc.2012.06.017_b0150","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2009.05.024","article-title":"Soluble fibrillar oligomer levels are elevated in Alzheimer\u2019s disease brain and correlate with cognitive dysfunction","volume":"35","author":"Tomic","year":"2009","journal-title":"Neurobiol. Disease"},{"key":"10.1016\/j.bbrc.2012.06.017_b0155","doi-asserted-by":"crossref","first-page":"210e1","DOI":"10.1016\/j.neurobiolaging.2011.09.016","article-title":"Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer\u2019s disease in a southern Chinese population","volume":"33","author":"Chen","year":"2012","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.bbrc.2012.06.017_b0160","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2012.06.017_b0165","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","article-title":"Rogers J Soluble amyloid \u03b2 peptide concentration as a predictor of synaptic change in Alzheimer disease","volume":"155","author":"Lue","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2012.06.017_b0170","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","article-title":"Soluble pool of A\u03b2 amyloid as a determinant of severity of neurodegeneration in Alzheimer disease","volume":"46","author":"McLean","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbrc.2012.06.017_b0175","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ana.410230206","article-title":"Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques","volume":"23","author":"Katzman","year":"1988","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbrc.2012.06.017_b0180","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid \u03b2 protein potently inhibit hippocampal long-term potentiation in vivo","volume":"416","author":"Walsh","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2012.06.017_b0185","doi-asserted-by":"crossref","first-page":"10191","DOI":"10.1523\/JNEUROSCI.3432-04.2004","article-title":"Synaptic targeting by Alzheimer\u2019s-related amyloid \u03b2 oligomers","volume":"24","author":"Lacor","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbrc.2012.06.017_b0190","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature04533","article-title":"A specific amyloid-\u03b2 protein assembly in the brain impairs memory","volume":"440","author":"Lesn\u00e9","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2012.06.017_b0195","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","article-title":"A\u03b2 oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer\u2019s disease","volume":"27","author":"Lacor","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbrc.2012.06.017_b0200","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1523\/JNEUROSCI.4970-06.2007","article-title":"Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor dependent signaling pathway","volume":"27","author":"Shankar","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbrc.2012.06.017_b0205","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-\u03b2 protein dimers isolated directly from Alzheimer\u2019s brain impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2012.06.017_b0210","doi-asserted-by":"crossref","first-page":"10369","DOI":"10.1523\/JNEUROSCI.5721-09.2010","article-title":"Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies","volume":"30","author":"Hillen","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbrc.2012.06.017_b0215","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jneumeth.2008.09.002","article-title":"Characterisation of two antibodies to oligomeric A beta and their use in ELISAs on human brain tissue homogenates","volume":"176","author":"van Helmond","year":"2009","journal-title":"J. Neurosci. Meth."},{"key":"10.1016\/j.bbrc.2012.06.017_b0220","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1113\/jphysiol.2005.103754","article-title":"Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers","volume":"572","author":"Townsend","year":"2006","journal-title":"J. Physiol."},{"key":"10.1016\/j.bbrc.2012.06.017_b0225","doi-asserted-by":"crossref","first-page":"10417","DOI":"10.1073\/pnas.1834302100","article-title":"Alzheimer\u2019s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss","volume":"100","author":"Gong","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1201090X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1201090X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T22:40:17Z","timestamp":1561848017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X1201090X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0006291X1201090X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2012.06.017","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}